Table 2.

Survival results at different time points for treatment groups

Cohort	Treatment	N	1-yr overall survival (95% CI)	3-yr overall survival (95% CI)	5-yr overall survival (95% CI)
All patients	RC with NAC	506	85% (81–87%)	56% (51–60%)	46% (41–51%)
	RC without NAC	1472	79% (77–81%)	51% (49–54%)	41% (38–43%)
	TMT with preferred chemotherapy	163	81% (73–86%)	51% (42–59%)	37% (28–46%)
	TMT with nonpreferred chemotherapy	165	75% (67–81%)	41% (32–49%)	24% (16–32%)
Patient age ≥65 yr	RC with NAC	266	86% (81–89%)	55% (48–61%)	44% (37–50%)
	RC without NAC	882	77% (74–80%)	47% (44–51%)	37% (34–40%)
	TMT with preferred chemotherapy	129	83% (74–88%)	53% (43–62%)	40% (29–50%)
	TMT with nonpreferred chemotherapy	143	73% (65–80%)	39% (30–48%)	22% (14–30%)
Patient age <65 yr	RC with NAC	240	83% (78–87%)	56% (49–62%)	49% (41–55%)
	RC without NAC	590	83% (80–86%)	57% (52–61%)	46% (42–51%)
	TMT with preferred chemotherapy	34	70% (50–83%)	37% (17–56%)	18% (5–38%)
	TMT with nonpreferred chemotherapy	22	80% (55–92%)	50% (27–69%)	31% (10–55%)

CI = confidence interval; NAC = neoadjuvant chemotherapy; RC = radical cystectomy; TMT = trimodal therapy.

Preferred chemotherapy includes cisplatin or mitomycin-C/5-fluorouracil.